Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Common Equity (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Common Equity for 3 consecutive years, with $218.9 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Common Equity fell 33.11% year-over-year to $218.9 million, compared with a TTM value of $218.9 million through Sep 2021, down 33.11%, and an annual FY2020 reading of $307.8 million, up 752.62% over the prior year.
  • Common Equity was $218.9 million for Q3 2021 at Black Diamond Therapeutics, down from $251.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $355.3 million in Q1 2020 and bottomed at -$47.2 million in Q4 2019.
  • Average Common Equity over 3 years is $177.0 million, with a median of $251.0 million recorded in 2021.
  • The sharpest move saw Common Equity soared 1942.76% in 2020, then plummeted 33.11% in 2021.
  • Year by year, Common Equity stood at -$47.2 million in 2019, then soared by 752.62% to $307.8 million in 2020, then decreased by 28.86% to $218.9 million in 2021.
  • Business Quant data shows Common Equity for BDTX at $218.9 million in Q3 2021, $251.0 million in Q2 2021, and $280.8 million in Q1 2021.